These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19024580)

  • 1. [A hope for multidrug-resistant tuberculosis?].
    Nau JY
    Rev Med Suisse; 2008 Oct; 4(175):2233. PubMed ID: 19024580
    [No Abstract]   [Full Text] [Related]  

  • 2. Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis.
    Yew WW; Chau CH; Wen KH
    Int J Tuberc Lung Dis; 2008 Mar; 12(3):345-6. PubMed ID: 18284844
    [No Abstract]   [Full Text] [Related]  

  • 3. Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis.
    Boutoille D; Grossi O; Depatureaux A; Tattevin P
    Eur J Intern Med; 2009 Oct; 20(6):e134-5. PubMed ID: 19782904
    [No Abstract]   [Full Text] [Related]  

  • 4. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis.
    Nam HS; Koh WJ; Kwon OJ; Cho SN; Shim TS
    Int J Antimicrob Agents; 2009 Jan; 33(1):92-3. PubMed ID: 18789655
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Sotgiu G; Lange C; Richardson MD; Matteelli A; Centis R; Eker B; Guenther G; Spanevello A; Migliori GB;
    J Antimicrob Chemother; 2009 Oct; 64(4):879-83; author reply 883-4. PubMed ID: 19651787
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Yew WW; Chang KC; Chau CH
    J Antimicrob Chemother; 2009 Nov; 64(5):1119; author reply 1119-20. PubMed ID: 19666903
    [No Abstract]   [Full Text] [Related]  

  • 7. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.
    Koh WJ; Shim TS
    J Antimicrob Chemother; 2009 Nov; 64(5):1119-20. PubMed ID: 19744986
    [No Abstract]   [Full Text] [Related]  

  • 8. Linezolid for multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Daley CL
    Lancet Infect Dis; 2012 Jul; 12(7):502-3. PubMed ID: 22742623
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].
    Valencia ME; Moreno V; Laguna F; González-Lahoz JM
    Enferm Infecc Microbiol Clin; 2001 Jan; 19(1):37-9. PubMed ID: 11256251
    [No Abstract]   [Full Text] [Related]  

  • 10. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis.
    Heilig CM; Chia D; El-Sadr WM; Hirsch-Moverman Y; Kenzie WR; Saukkonen J; Villarino ME; Padayatchi N
    IRB; 2011; 33(4):10-7. PubMed ID: 21932482
    [No Abstract]   [Full Text] [Related]  

  • 11. [Linezolid, an agent from a new class of antibiotics].
    Slebos DJ; Van Altena R
    Ned Tijdschr Geneeskd; 2004 Dec; 148(49):2462; author reply 2462-3. PubMed ID: 15626313
    [No Abstract]   [Full Text] [Related]  

  • 12. Optic neuropathy secondary to Linezolid for multidrug-resistant mycobacterial spinal tuberculosis.
    Agrawal R; Addison P; Saihan Z; Pefkianaki M; Pavesio C
    Ocul Immunol Inflamm; 2015 Feb; 23(1):90-2. PubMed ID: 24432953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid for multidrug-resistant tuberculosis.
    Cox H; Ford N; Hughes J; Goemaere E
    Lancet Infect Dis; 2013 Jan; 13(1):16. PubMed ID: 23257228
    [No Abstract]   [Full Text] [Related]  

  • 14. Linezolid for multidrug-resistant tuberculosis - authors' reply.
    Chang KC; Leung CC; Daley CL
    Lancet Infect Dis; 2013 Jan; 13(1):16-7. PubMed ID: 23257227
    [No Abstract]   [Full Text] [Related]  

  • 15. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.
    Sotgiu G; Centis R; D'Ambrosio L; Castiglia P; Migliori GB
    Eur Respir J; 2015 Jan; 45(1):287-9. PubMed ID: 25552740
    [No Abstract]   [Full Text] [Related]  

  • 16. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.
    Weiss T; Schönfeld N; Otto-Knapp R; Bös L; Bettermann G; Mauch H; Bauer TT; Rüssmann H
    Eur Respir J; 2015 Jan; 45(1):285-7. PubMed ID: 25552739
    [No Abstract]   [Full Text] [Related]  

  • 17. Linezolid resistant enterococcus faecium.
    McNicholas S; Hanahoe B; Higgins F; McAnena O; Corbett-Feeney G; Cormican M
    Ir Med J; 2008; 101(7):225-6. PubMed ID: 18810787
    [No Abstract]   [Full Text] [Related]  

  • 18. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
    J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid for multidrug-resistant tuberculosis: How should we approach it?
    Santin M
    Enferm Infecc Microbiol Clin; 2016 Feb; 34(2):83-4. PubMed ID: 26795055
    [No Abstract]   [Full Text] [Related]  

  • 20. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.
    Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB;
    Eur Respir J; 2013 Jul; 42(1):288-90. PubMed ID: 23813314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.